Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Blackstone Inc (BX) vs Cassava Sciences Inc (FLNA) Price & Performance

Blackstone IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Blackstone Inc vs Cassava Sciences Inc — how do they compare? Blackstone Inc trades at $145.15 (market cap $117.44B), while Cassava Sciences Inc trades at $0.94 (market cap $47.75M). The key difference: Blackstone Inc is far larger — about 2459.5× Cassava Sciences Inc's market cap, and Blackstone Inc pays a 3.55% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

BXFLNA
Market Cap
$117.44B$47.75M
Sector
FinancialsHealth
52-Week High
$188.68$4.64
52-Week Low
$102.12$0.87
Dividend Yield
3.55%
Enterprise Value
-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Blackstone Inc

Blackstone (BX) trades at $141.67, up 3.31% today, near its consensus price target of $144.00. The stock shows strong bullish technical signals and has consistently beaten earnings estimates in recent quarters. Recent news highlights strategic acquisitions, including a stake in Air Canada's Aeroplan program and a $25.3 billion Australian home loan portfolio purchase from HSBC, signaling aggressive growth and diversification.

Outlook remains positive with robust revenue growth and high profitability, though elevated valuation ratios and overbought RSI levels suggest near-term caution. Key risks include market volatility and integration challenges from recent deals. Analyst consensus is strongly bullish, supporting a favorable long-term view.

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Blackstone Inc

Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.

Read more on BX

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA